Citations

Clear

13603 citation(s) found for "_, _".

Colorectal cancer screening barriers, facilitators, and promotion recommendations by Alaska Native people who are non‐adherent to colorectal cancer screening
Toffolon, Melissa, Jeffries, Lauren , Bailie, Danika, Rutten, Lila Finney, Kisiel, John, Redwood, Diana , Flanagan, Christie A. , Jeffries, Lauren, Kisiel, John B.

Mayo Clinic

The Journal of Rural Health | August 6, 2025 | Volume: 41 | Issue: 3 | Pages: No page available

10.1111/jrh.70067 | PMID 40765125 Get It

Abstract Purpose We examined barriers and facilitators to colorectal cancer (CRC) screening among Alaska Native individuals who had never been screened or were not up to date with screening guidelines. Methods As part of a larger study investigating the use of the multitarget stool DNA test in rural Alaska communities, we conducted focus groups and in‐depth interviews with 28 never screened or not up‐to‐date Alaska Native people in two remote communities between November 2022 and July 2023. Participants shared their barriers to CRC screening and offered suggestions to improve programs to better reach those who are guideline discordant. Findings General screening barriers included lack of knowledge, fear of discovering you have cancer, and cultural health beliefs. Colonoscopy‐specific barriers included embarrassment from knowing the local medical staff, having rectal area viewed or touched, fear of pain and injury, difficulty scheduling a procedure due to traditional food gathering activities, lack of provider referrals/reminders, and the high cost of air travel required to get to a colonoscopy facility. Stool DNA‐specific concerns included not feeling that it was as good as colonoscopy, lack of privacy to do the test, and hesitancy collecting stool samples. Suggestions for increasing screening rates included increasing access via paid air transportation, using local indigenous languages, improving provider relationships and reminder systems, and providing CRC and screening education using trusted messengers. Conclusions This was the first exploration of the perceptions of CRC screening among guideline discordant Alaska Native people. Identified themes can be used to improve screening program outreach effectiveness in the future.
Characteristics, Interventions, and Outcomes for Patients Presenting to the Emergency Department With Abdominal Pain
Ghaith, Summer , Ginsberg, Zachary , McElhinny, Megan L. , Jones, Derick D. , Lindor, Rachel A. , McElhinny, Megan , Jones, Derick D , Lindor, Rachel A , Campbell, Ronna L. , Mullan, Aidan F.

Mayo Clinic

Academic Emergency Medicine | August 6, 2025 | Volume: 33 | Issue: 1 | Pages: No page available

10.1111/acem.70110 | PMID 40764816 Get It

ABSTRACT Objective We sought to characterize patients presenting to emergency departments (EDs) with abdominal pain and to validate risk categories defined by the Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE‐2) for low‐risk recurrent abdominal pain. Methods We conducted a retrospective cohort study of patients presenting with abdominal pain between November 2019 and November 2023 across 21 EDs in Arizona, the Midwest, and Florida. Patients were categorized per GRACE‐2 into recurrent and non‐recurrent pain as well as low‐ and high‐risk groups. Primary outcomes included 72‐h returns and mortality at 30 and 90 days. Results The study included 162,494 visits (112,896 unique patients; median age 46 years; 61.2% female). Among these, 4.3% had low‐risk recurrent abdominal pain. Patients with recurrent and non‐recurrent low‐risk pain had similar ED length of stay and discharge rates to each other, compared to patients with high‐risk pain who had longer length of stay and lower discharge rates. At 30 days after the ED encounter, patients with low‐risk recurrent abdominal pain had similar mortality to patients with low‐risk non‐recurrent pain (0.4% vs. 0.3%; adjusted RR = 1.31, 95% CI: 0.85–2.03), while they had significantly lower mortality than patients with high‐risk recurrent abdominal pain (0.4% vs. 2.3; adjusted RR = 3.14, 95% CI: 2.02–4.89). Conclusions This study highlights the heterogeneity in patients presenting to the ED with abdominal pain. Among these patients, those with low‐risk recurrent pain demonstrated similar lengths of stay, discharges, and mortality rates to those with low‐risk non‐recurrent pain and less favorable lengths of stay, discharges, and mortality rates compared to those with any high‐risk features. These findings suggest that low‐ and high‐risk features may be more useful than recurrent or non‐recurrent pain in identifying patients who could benefit from more robust ED evaluations.
Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benedetti, Daniel J. , Brown, Brandon , Cook, Shelly, Desai, Ami V. , Fair, Douglas , Hiniker, Susan M. , Jasty‐Rao, Rama, Just, Marissa, Kieran, Kathleen , Lin, Chi , MacEwan, Iain, Martínez-Agosto, Julián A. , Mullen, Elizabeth A. , Murphy, Erin S. , Ranalli, Mark , Rhee, Daniel S. , Wickiser, Jonathan E., Yoon, Janet, Zapala, Matthew A. , Sliker, Bailee , Horst, Kelly , Balis, Frank M. , Green, Daniel M. , Armstrong, Amy J. , Aye, Jamie M. , Brown, Brandon Douglas , Brown, Erin G. , Dhillon, Jasreman , Geynisman, Daniel M. , Horst, Kelly K. , Pinto, Navin , Rokitka, Denise A. , Walz, Amy L. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 319-342

10.6004/jnccn.2025.0037 | PMID 40763792 Get It

The NCCN Clinical Practice Guidelines (NCCN Guidelines) for Wilms Tumor (WT; nephroblastoma) cover strategies for the screening, diagnosis, and treatment of WT, which is the most frequent primary kidney tumor in children. WT can generally be separated into 2 histology types: favorable histology WT and anaplastic WT. Five-year survival is high for children with favorable histology WT who receive appropriate treatment; however, survival rates are much lower for patients who present with higher stage diffuse anaplastic WT. Treatment of WT can range from surgery alone to surgery plus intensive chemotherapy and radiation depending on whether the tumor is unilateral or bilateral, histology, and local stage. The goal of therapy is to maximize cure while minimizing long-term toxicities. The content featured in this issue covers the NCCN panel’s recommendations for overall management of both favorable histology WT and anaplastic WT.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Abu‐Rustum, Nadeem R. , Campos, Susana M. , Amarnath, Sudha, Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Landrum, Lisa M. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nieto, Karina , Nwachukwu, Chika , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Sisodia, Rachel, Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Arend, Rebecca C. , Crispens, Marta Ann , Gaillard, Stéphanie , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 284-291

10.6004/jnccn.2025.0038 | PMID 40763788 Get It

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annually to review comments from reviewers within their institutions; examine relevant new data from publications, abstracts, and recent FDA approvals; and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.
Authors’ Reply to the Letter to the Editor by Takefuji: Methodological Limitations in Breast Cancer Survivorship Research: Beyond Linear Regression
Ehlers, Shawna L. , Ruddy, Kathryn J. , Vierkant, Robert A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: No page available

10.6004/jnccn.2025.7083 | PMID 40763783 Get It

A Century After Jacobson v. Massachusetts: Public Health Ethical Perspectives of Large Language Models on Vaccination
Mugu, Vamshi , Kandimalla, Mahathi, Mugu, S. Ruthvik, Sharma, Kshipra

Mayo Clinic

2025 IEEE International Symposium on Ethics in Engineering, Science, and Technology (ETHICS) | August 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/ethics65148.2025.11098289 Get It

Use of Personalized Body-Worn Alcohol Dispenser, Without Practitioner Feedback, on Bacterial Transmission, Hourly Hand Decontamination Events, and Practitioner Hand Contamination: A Multicenter Randomized Controlled Study
Dexter, Franklin , Togioka, Brandon M. , Simmons, Colby G. , Parra, Michelle C. , Koff, Matthew D. , Wanta, Brendan T., Fernandez, Patrick, Charnin, Jonathan E. , Loftus, Randy W. , Pugely, Andrew J. , Brown, Jeremiah R.

Mayo Clinic

Anesthesia & Analgesia | August 4, 2025 | Volume: 142 | Issue: 1 | Pages: 205-209

10.1213/ane.0000000000007671 | PMID 40758582 Get It

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
Dhakal, Binod , Akhtar, Othman Salim , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed, Martinez, Mariola Alejandra Vazquez, Wagner, Charlotte B , Davis, James A. , Afrough, Aimaz , Bhutani, Manisha , Freeman, Ciara L. , Mikkilineni, Lekha , Raza, Shahzad , Anderson, Larry D. , Kapoor, Prashant , Hosoya, Hitomi , Gaballa, Mahmoud , Midha, Shonali , Alsina, Melissa , Sborov, Douglas W. , Patel, Krina K. , Lin, Yi , Ferreri, Christopher J. , Kumar, Anupama, Cowan, Andrew J., Sidana, Surbhi , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed , Vazquez-Martinez, Mariola A , Wagner, Charlotte , Davis, James A , Castaneda Puglianini, Omar , Dima, Danai , Bhutani, Manisha , Parrondo, Ricardo D , Freeman, Ciara L , Anderson, Larry D , Hosoya, Hitomi , Chhabra, Saurabh , Grajales-Cruz, Ariel F , Sborov, Douglas W , Patel, Krina , Hansen, Doris K , Costa, Luciano J , Merz, Maximilian , Sidana, Surbhi , Raza, Shahzad , Dhakal, Binod , Fandrei, David , Pan, Darren , Richard, Shambavi , Rees, Matthew J. , Costello, Patrick , Vazquez‐Martinez, Mariola , Pasvolsky, Oren , Puglianini, Omar Castañeda , Reshef, Ran , Dima, Danai , Nadeem, Omar , Chhabra, Saurabh , Grajales‐Cruz, Ariel , Gagelmann, Nico , Hansen, Doris K. , Costa, Luciano J. , Merz, Maximilian

Mayo Clinic

Blood | August 1, 2025 | Volume: 146 | Issue: 17 | Pages: 2063-2072

10.1182/blood.2025029773 | PMID 40749169 Get It

Abstract Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), 2 B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR-T) therapies, have transformed outcomes for relapsed/refractory multiple myeloma; however, the 6 to 8 weeks manufacturing time risks disease progression or death in up to 10% of patients. Talquetamab, a G-protein–coupled receptor, family C, group 5, member D (GPRC5D)–targeting bispecific antibody, represents a promising option. We performed a multi-institutional retrospective analysis across 20 centers (18 United States, 2 Germany) evaluating talquetamab as a bridging therapy prior to cilta-cel or ide-cel. Among 134 patients receiving talquetamab, 119 proceeded to CAR-T (n = 98 cilta-cel, n = 21 ide-cel). Reasons for not proceeding (n = 15) included progression (n = 7), manufacturing failure (n = 6), or patient decision (n = 2). Median age was 65 years and had median 5 prior lines of therapy. Notably, 85% would not have met CARTITUDE-1/KarMMa eligibility criteria. Talquetamab was administered for a median 23 days. Toxicity was manageable: no grade ≥3 cytokine release syndrome (CRS), 2% grade 3 immune effector cell–associated neurotoxicity syndrome (ICANS) and grade 1 to 2 talquetamab unique toxicities (70% oral, 38% skin, and 17% nail; 60% resolved). Talquetamab achieved 71% response rate. After CAR-T, 88% responded (54% complete response), with low-grade toxicities (2 grade ≥3 CRS, 1 grade 3 ICANS, and 5% grade ≥3 infections). Two cases of facial palsy and 1 acute myeloid leukemia occurred. Talquetamab correlated with sustained soluble BCMA decline and peak CAR-T expansion around day 14. Talquetamab bridging appears safe, enabling the majority of difficult-to-treat patients to successfully proceed to BCMA CAR-T therapy.
Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis
Brown, Gabrielle, Miller, Avital M. , Jaoude, Joseph Abi , Ludmir, Ethan B. , Sherry, Alexander D. , Miller, Avital M , Abi Jaoude, Joseph , Ludmir, Ethan B , Sherry, Alexander D , Brown, Gabrielle, Msaouel, Pavlos , Kouzy, Ramez , Lin, Timothy A.

Mayo Clinic

Cancer Medicine | August 1, 2025 | Volume: 14 | Issue: 15 | Pages: No page available

10.1002/cam4.71097 | PMID 40879280 Get It

ABSTRACT Background Blinding mitigates bias in randomized trials and may be especially crucial for surrogate endpoints, such as progression‐free survival (PFS). Here, we characterize utilization of and factors associated with blinding in Phase III oncology trials with PFS primary endpoints. Methods Two‐arm, superiority‐design trials investigating systemic therapy were identified in May 2024 from ClinicalTrials.gov with no date limitation. Trials were required to have a PFS primary endpoint. The study outcomes were the presence of double‐blind designs and blinded independent central review (BICR) for the primary endpoint. Ninety‐five percent credible intervals for binary outcomes were estimated from beta distributions, and multivariable logistic regressions explored associations with trial‐level features. Results After screening, 237 trials were included, enrolling 127,518 patients. A double‐blind design was used in 105 trials (44%, 95% CrI 38%–51%). BICR was used in 111 trials (47%, 95% CrI 41%–53%), including 39 double‐blind trials (16%, 95% CrI 12%–22%). Trials with BICR had higher odds of meeting the primary endpoint (OR 1.84; 95% CI 1.06–3.18; p = 0.03). The PFS assessor identity (central vs. local) or blinding status was not reported in 50 trials (26%, 95% CrI 16%–27%). Trials that met prespecified significance criteria for PFS were more likely to report whether PFS assessors were blinded/unblinded and central/local (OR, 3.05; 95% Cl: 1.60–5.81; p = 0.0007). Conclusions Despite the importance of double blinding in combination with BICR for reducing bias, only a few trials blinded physicians, patients, and primary endpoint assessors. This meta‐epidemiological study illuminates the prevalence of potential assessment biases affecting PFS in Phase III oncology and secondarily emphasizes the need for improved methodology reporting.
Comparative analysis of robotic, laparoscopic, and open ileal pouch–anal anastomosis outcomes: retrospective cohort study
Violante, Tommaso , Broccard, Sacha P. , Novelli, Marco , Stocchi, Luca , Colibaseanu, Dorin , DeLeon, Michelle , Behm, Kevin T. , Mishra, Nitin , Larson, David W. , Merchea, Amit , Colibaseanu, Dorin T , DeLeon, Michelle F, Violante, Tommaso , Broccard, Sacha , Larson, David W

Mayo Clinic

BJS Open | July 31, 2025 | Volume: 9 | Issue: 4 | Pages: No page available

10.1093/bjsopen/zraf084 | PMID 40742352 Get It

Abstract Introduction Ileal pouch–anal anastomosis (IPAA) is a common surgical procedure for patients with ulcerative colitis or familial adenomatous polyposis. This study compared the outcomes of robotic, laparoscopic, and open IPAA techniques, with a focus on surgical complications and pouch failure rates. Methods A retrospective study was conducted of patients who underwent IPAA at three Mayo Clinic locations between 2015 and 2020. Data on patient demographics, surgical details, and postoperative outcomes were collected and compared across the three surgical approaches. Pouch failure was defined as the need for pouch excision or a diverting loop ileostomy. Results In all, 401 patients underwent IPAA with either an open (149, 37.2%), robotic (145, 36.2%), or laparoscopic (107, 26.7%) technique. The overall rate of pouch failure was 6.5% and did not differ significantly between the three surgical approaches. Compared with laparoscopy, robotic IPAA was associated with a lower conversion rate to open surgery (1.4 versus 17.8%; P < 0.0001) and fewer 30-day readmissions (15.9% versus 28.0%; P = 0.02). However, robotic and laparoscopic IPAA approaches had higher rates of venous thromboembolism/pulmonary embolism and readmission than the open approach. Pouchitis was the most common cause of pouch failure across all surgical techniques. Conclusion Robotic IPAA had lower conversion and reduced 30-day admission rates compared with a laparoscopic approach. However, open surgery had lower rates of 30-day readmission and rates thromboembolism than robotic IPAA. The surgical approach itself does not appear to significantly impact long-term pouch failure rates.